Drug Discovery

At the very sites where arteries branch and curve, the blood’s mechanical turbulence quietly erodes endothelial defenses while seeding DNA injury that stokes plaque formation yet, paradoxically, also triggers a built-in metabolic countermeasure. New research led by Baylor College of Medicine and

Nineteen protein subunits arranged in a near-perfect circle gripped a frayed DNA end, and that spare geometry—simple, symmetric, and relentless—reshaped how a critical cancer target might be stopped. The ring belonged to Mgm101, a yeast mitochondrial homolog of human RAD52, and under a convergence

Signals from a pivotal trial now cut through the noise of a crowded obesity market, forcing hard questions about where dual agonists belong and how quickly they can reshape care. Obesity has shifted from a lifestyle narrative to a biologic disease with organ-level consequences, most notably in the

A disease that steals movement while leaving thought intact demanded more than incremental symptom care, and that urgency set the stage for a candidate built to confront the fault line where motor neurons first begin to fail. AP-2, now entering first-in-human testing at La Princesa University

Hospitals feel the squeeze as drug-resistant infections outpace discovery, while conventional screening drains time and money without delivering medicines that dissolve, distribute, and survive the real world. That pressure has pushed researchers to reimagine how drugs are created, trading

Ivan Kairatov brings a biopharma lens to one of the most sensitive decisions in pediatrics: when to give the first hepatitis B vaccine. With a research-and-development background rooted in tech and innovation, he translates probabilistic modeling, clinical epidemiology, and practical workflows into